May 9, 2024
The American College of Radiology® (ACR®) responded to a targeted request for information from U.S. Rep. Ami Bera, MD, (CA-6), a member of the bipartisan House Task Force on Artificial Intelligence (AI), regarding the state of health care artificial intelligence (AI). Rep. Bera’s RFI included an extensive list of questions focused on various aspects of healthcare AI oversight, implementation, use and innovation.

ACR highlighted examples of real-world applications of healthcare AI and recommended ways to enhance product transparency and oversight mechanisms moving forward, including leveraging public-private partnerships. The College provided concepts that would be important in any future value-based payment approach looking at ensuring quality implementation, governance and use of high-value AI tools. ACR noted that not all currently reimbursed uses of AI are adding value to patients or the health system.

ACR also highlighted novel oversight questions posed by foundation models/generative AI used to enable higher risk functions such as diagnosis or treatment. The College noted the U.S. Food and Drug Administration may benefit from expanded authorities to meet future regulatory challenges and opportunities.

For more information about ACR’s AI-related programs and initiatives, visit the ACR Data Science Institute website. For questions about the ACR comment submission or AI oversight policy, contact Michael Peters, ACR Senior Government Affairs Director.

Related ACR News

  • ACR Attends 2025 RUC Meetings

    ACR participated in the American Medical Association/Specialty Society RVS Update Committee meeting where they heard updates on the AMA Physician Practice Information Survey.

    Read more
  • NCI Releases FY 2027 Budget Proposal

    Anthony Letai, MD, PhD, became NCI Director Sept. 29, leading with a $7.2B budget and proposing $11.5B for FY 2027 to boost cancer research.

    Read more
  • Lead the Future of Alzheimer's Imaging

    Join ALZ-NET Imaging Network to access AI tools, boost Alzheimer’s imaging, and contribute data to shape FDA safety and clinical guidelines.

    Read more